SynthesisBMC oral health2026
Oral manifestations in HIV-positive individuals under highly active antiretroviral therapy: a systematic review and meta-analysis of prevalence data.
Synthesis in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
This study aims to analytically explore the prevalence of oral manifestations in HIV-positive patients who are receiving or are not receiving highly active antiretroviral therapy (HAART). Electronic search was conducted at multiple databases (PubMed, Embase, LILACS, SciELO, Scopus and Web of Science) and gray literature was also assessed (ProQuest and EASY databases). JBI Critical Appraisal Tools were used to establish methodological quality. Data from each study was combined in a meta-analysis of proportions using an inverse variance method, Freeman-Tukey double arcsine transformation, and Clopper-Pearson confidence interval. Quality of evidence was determined via Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach. The search yielded 25 eligible articles, with quantitative synthesis from 13. Only four studies had a low risk of bias. The meta-analysis revealed a prevalence of oral manifestations in 42% (95% CI: 29% – 56%, I2 = 97%) of patients receiving HAART. Patients undergoing HAART were less likely to present oral manifestations (OR: 0.51; 95% CI: 0.27–0.94) than those in the non-HAART group, with a very low certainty of evidence. Although patients receiving HAART are less likely to present with oral manifestations, primary studies must be performed with a standardized methodology to guarantee results with a higher certainty of evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.